Kamada to Host a Virtual Analysts and Investors Meeting to Review its Growth Catalysts Rehovot, Israel

Kamada to Host a Virtual Analysts and Investors

Meeting to Review its Growth Catalysts

Rehovot, Israel, June 1, 2022 - Kamada

Ltd. (NASDAQ & TASE: KMDA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics,

today announced that it will host a virtual analysts and investors meeting on Tuesday, June 7, 2022, at 12:00 PM Eastern Time to review

its growth catalysts. To register for the meeting please see below.

The meeting will feature a presentation by Amir

London, Chief Executive Officer, Chaime Orlev, Chief Financial Officer, and Jon R. Knight, Vice President, U.S. Commercial Operations,

who will discuss Kamada's strategic evolution into a fully-integrated specialty plasma company with six FDA-approved products and

strong commercial capabilities in the U.S. market, as well as a global commercial footprint in over 30 countries.

The Company expects full-year 2022 total revenue

of $125 million to $135 million, which would represent a 20% to 30% increase over 2021 revenue, with EBITDA margins of 12-15%. Kamada

also anticipates generating revenue growth at a double-digit rate in the foreseeable years ahead.

The Company's key growth catalysts to be

presented in the meeting, include:

A live questions and answers session will follow

the formal presentation. To register for the meeting: https://lifesci.rampard.com/WebcastingAppv5/Events/Registration/registration.jsp?Y2lk=MTg3Mg==&Y2lk=MTg3Mg==

Kamada Ltd. (the "Company") is a vertically

integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, with a diverse portfolio of marketed products,

a robust development pipeline and industry-leading manufacturing capabilities. The Company's strategy is focused on driving profitable

growth from our current commercial activities as well as our manufacturing and development expertise in the plasma-derived biopharmaceutical

market. The Company's commercial products portfolio includes its developed and FDA approved products GLASSIA and KEDRAB

as well as its recently acquired FDA approved plasma-derived hyperimmune products CYTOGAM , HEPAGAM B , VARIZIG and WINRHO SDF.

The Company has additional four plasma-derived products which are registered in markets outside the U.S. The Company distributes its commercial

products portfolio directly, and through strategic partners or third-party distributors in more than 30 countries, including the U.S.,

Canada, Israel, Russia, Brazil, Argentina, India and other countries in Latin America and Asia. The Company has a diverse portfolio of

development pipeline products including an inhaled AAT for the treatment of AAT deficiency for which the Company is currently conducting

the InnovAATe clinical trial, a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial. The Company leverages its expertise

and presence in the Israeli pharmaceutical market to distribute in Israel more than 20 products that are manufactured by third parties

and have recently added eleven biosimilar products to its Israeli distribution portfolio, which, subject to EMA and the Israeli MOH approvals,

are expected to be launched in Israel between the years 2022 and 2028. FIMI Opportunity Fund, the leading private equity investor in Israel,

is the Company's lead shareholder, beneficially owning approximately 21% of the outstanding ordinary shares.

Chief Financial Officer

LifeSci Advisors, LLC